Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | ARG1 | P05089 | 2/20 | 0.36 |
| ▸ | ARG2 | P78540 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454150 | 0.88 | KCNA3 (0.39) | KCNA3SPHK1ARG1ARG2SIGMAR1 | |
| SCHEMBL2553857 | 0.88 | PDCD1 (0.40) | KCNA3HRH3HRH2HRH1 | |
| SCHEMBL8971344 | 0.86 | KCNA3 (0.38) | KCNA3SPHK1ARG1ARG2SIGMAR1 | |
| SCHEMBL8642327 | 0.84 | SPHK1 (0.40) | KCNA3SPHK1ARG1ARG2SIGMAR1 | |
| SCHEMBL18666615 | 0.79 | LTA4H (0.37) | ARG1ARG2SIGMAR1HRH3ACHE | |
| SCHEMBL2560880 | 0.78 | CARM1 (0.50) | SIGMAR1HRH3ACHE | |
| SCHEMBL2558774 | 0.78 | GNAI3 (0.46) | SPHK1SIGMAR1HRH3HRH2HRH1 | |
| SCHEMBL5362273 | 0.78 | — | — | |
| SCHEMBL16924642 | 0.78 | LTA4H (0.41) | HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL13996583 | 0.78 | GNAI3 (0.51) | KCNA3SPHK1ARG1ARG2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| CN-102791711-A | 1, 7-diazacarbazoles and their use in the treatment of cancer | HOFFMANN LA ROCHE | 2012-11-21 | — | — | CN | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |